Camptosar Label Revision Strengthens Monitoring Of Patients With Diarrhea
Executive Summary
Pharmacia Camptosar revised labeling strengthens recommendations on monitoring patients with diarrhea
You may also be interested in...
Pharmacia Plans Camptosar Submission For Labeling Change By Year-End
Pharmacia will submit a labeling change proposal for its colorectal cancer therapy Camptosar by the end of the year based on FDA's Oncologic Drugs Advisory Committee Dec. 6 review of postmarketing safety
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials